We are live on ! Find out more
IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Delisted

IMUC was delisted on the 16th of October, 2018.

Back to rankings

49 hedge funds and large institutions have $10.1M invested in ImmunoCellular Therapeutics, Ltd. in 2013 Q2 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more call options, than puts

Call options by funds: $934K | Put options by funds: $632K

Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
49
Increased
–
Reduced
–
Closed
–
Calls
$934K
Puts
$632K
Net Calls
+$302K
Net Calls Change
+$302K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

IMUC Hedge Fund Activity: Q2 2013 in Review

49 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2013, worth a combined $10.1M.

Buyers outnumbered sellers: 49 funds opened new IMUC positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

  • 49 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $10.1M of ImmunoCellular Therapeutics, Ltd. stock for Q2 2013.
  • 49 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2013 and 0 closed out, a net change of +49 holders.

Based on aggregated 13F filings for Q2 2013.